Efficacy and safety of chimeric antigen receptor-T cells in the treatment of B cell lymphoma:a systematic review and meta-analysis

作     者：Xiao-Hong Zheng Xi-You Zhang Qian-Qian Dong Feng Chen Shou-Bo Yang Wen-Bin Li Xiao-Hong Zheng;Xi-You Zhang;Qian-Qian Dong;Feng Chen;Shou-Bo Yang;Wen-Bin Li

作者机构：Departm ent of Neuro-OncologyNeurosurgery CenterBeijing Tiantan HospitalCapital Medical UniversityBeijing 100070China Department of NephrologyBeijing Shijitan HospitalCapital Medical UniversityBeijing 100038China Department of General MedicineNingbo Medical CenterLi Huili HospitalNingboZhejiang 315000China 

出 版 物：《Chinese Medical Journal》 (中华医学杂志（英文版）)

年 卷 期：2020年第133卷第1期

页      面：74-85页

核心收录：

学科分类：1001[医学-基础医学(可授医学、理学学位)] 100102[医学-免疫学] 10[医学] 

基　　金：This work was supported by grants from the National Natural Science Foundation of China(No.81470139) the Beijing Municipal Science&Technology Commission(No.Z181100001718127) 

主　　题：Lymphoma B-cell Meta-analysis Chimeric antigen receptor T-cell 

摘      要：Background:Conventional treatment has limited efficacy in relapsed/refractory B-cell *** chimeric antigen receptor T-cell(CAR-T)technology has shown high safety and results in high remission rates,we investigated its efficacy and safety in B-cell lymphoma treatment and analyzed potential affecting factors to provide evidence for therapeutic strategies and ***:We searched databases including PubMed,Embase,and Cochrane up to July ***-analysis 1 was conducted to study the efficacy of CAR-T cell for treating B-cell lymphoma,measuring the response rate and complete remission rate as ***-group analysis was performed for age,pathological type,target antigen,co-stimulatory molecule,and conditioning ***-analysis 2 was undertaken on the safety of the treatment with the incidence rate of toxicity(cytokine-releasing syndrome[CRS],neurotoxicity)as an ***:Seventeen studies were included in the systematic review and *** was found that CAR-T cells had good therapeutic effects in the following cases:B-cell lymphoma(patients≥65 years old);diffuse large B-cell lymphoma pathological type;patients with treatment target antigen other than CD19;patients treated with co-stimulatory molecules other than CD28,including 4-1BB+CD28 or 4-1BB;and patients treated with cyclophosphamide/fludarabine pre-treatment protocol conditioning *** the CRS and neurotoxicity incidences were high,most were reversible with minimal risk of ***:CAR-T cell treatment is safe for clinical application;however,toxicity effects should be monitored.